Manja Boerman, native Dutch, is the President of Catalent Cell & Gene Therapy with overall responsibility for strategy and leadership of the cell and gene businesses. She has more than 20 years’ experience in biotech and pharmaceutical services, and significant experience as a senior executive in start-up environments and global late-stage clinical development for cell therapy products.

She has held several executive leadership positions at previous companies including President of Aesica Pharmaceuticals, President of Patheon Biologics, President of DSM Biologics and she served as CEO of biotech companies Kiadis Pharma and Regenesance. Manja started her career at DSM and held multiple business development and licensing and technology roles within DSM Biologics. She holds a PhD in Biochemistry from the State University of New York.